Eli Lilly and Company $LLY Stock Purchased by AlphaCore Capital LLC

Key Points

• AlphaCore Capital increased its Eli Lilly stake by 23.3% in the third quarter, adding 3,187 shares to bring its holdings to 16,879 shares, valued at $19.53 million. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $1,416.64; several brokerages recently raised their targets.
• Lilly reported quarterly earnings of $7.48 per share, beating the $5.71 consensus estimate, while revenue rose 38.6% year over year to $24.40 billion.

AlphaCore Capital LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 23.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,879 shares of the company's stock after purchasing an additional 3,187 shares during the period. AlphaCore Capital LLC's holdings in Eli Lilly and Company were worth $19,530,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Retirement Systems of Alabama lifted its stake in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Retirement Systems of Alabama now owns 246,991 shares of the company's stock worth $285,788,000 after acquiring an additional 50,578 shares during the period. Palacios Wealth Management LLC raised its holdings in Eli Lilly and Company by 9.3% during the third quarter. Palacios Wealth Management LLC now owns 914 shares of the company's stock worth $1,058,000 after purchasing an additional 78 shares in the last quarter. Private Management Group Inc. raised its holdings in Eli Lilly and Company by 11.4% during the third quarter. Private Management Group Inc. now owns 615 shares of the company's stock worth $712,000 after purchasing an additional 63 shares in the last quarter. Clear Wave Wealth Management LLC lifted its position in Eli Lilly and Company by 2.7% in the third quarter. Clear Wave Wealth Management LLC now owns 908 shares of the company's stock valued at $1,051,000 after purchasing an additional 24 shares during the period. Finally, Joseph Group Capital Management lifted its position in Eli Lilly and Company by 0.7% in the third quarter. Joseph Group Capital Management now owns 5,280 shares of the company's stock valued at $6,109,000 after purchasing an additional 39 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on LLY. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Scotiabank boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a "sector outperform" rating in a report on Friday, October 30th. Berenberg Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 target price on the stock in a research report on Tuesday, September 15th. The Goldman Sachs Group reissued a "buy" rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Finally, Argus upped their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,416.64.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,413.22 on Tuesday. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00. The firm has a 50 day moving average price of $1,220.13 and a 200 day moving average price of $1,102.83. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.87, a PEG ratio of 1.77 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter in the previous year, the business earned $7.02 EPS. The company's revenue for the quarter was up 38.6% on a year-over-year basis. Sell-side analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is 22.46%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.